|Bid||0.00 x 40000|
|Ask||0.00 x 1800|
|Day's Range||61.85 - 63.13|
|52 Week Range||57.17 - 74.12|
|Beta (5Y Monthly)||0.38|
|PE Ratio (TTM)||17.62|
|Earnings Date||Jul 27, 2022 - Aug 01, 2022|
|Forward Dividend & Yield||2.92 (4.63%)|
|Ex-Dividend Date||Jun 14, 2022|
|1y Target Est||69.21|
One great way to make passive income is to invest in dividend stocks. Here's why they selected AbbVie (NYSE: ABBV), Gilead Sciences (NASDAQ: GILD), and Merck (NYSE: MRK). Keith Speights (AbbVie): Only the most elite dividend stocks become Dividend Kings.
Gilead (GILD) Hepcludex meets the primary endpoint in a phase III study for the treatment of chronic hepatitis delta virus (HDV) infection at 48 weeks.
Gilead is as passionately committed to championing inclusion and diversity, health equity and social justice issues, as it is to helping improve the lives of people with life-threatening diseases. ...